Danaher Corporation (DHR)
Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside
Danaher is positioned for a revenue rebound, led by strong bioprocessing demand and resilient recurring sales, despite short-term headwinds in Life Sciences and China. Margin outlook is stable, supported by a $150M cost-cutting program and proactive tariff mitigation. Shares trade below their 5-year average P/E, offering compelling upside, as growth recovers and margin initiatives take hold.
CVS vs. DHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Danaher: High Capex And Low Debt Despite Trump Legislation
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher invested 25.81% of its revenues to expand its operations, which has contributed to the growth rate of its revenues.
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Partners With AstraZeneca to Support Precision Medicine
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
CVS or DHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Here's Why Investors Should Consider Retaining Danaher Stock Now
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR ) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team and I'm excited to host our next session.
CVS vs. DHR: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Danaher: Q1 Beat Fails To Trigger Guidance Upgrade
Danaher's management appears to be strategically keeping the stock price depressed to complete its share buyback program and capitalize on lower acquisition target valuations. The company delivered better-than-expected Q1 2025 results, driven by strong performance in biotechnology and molecular diagnostics, despite maintaining conservative guidance. DHR has repurchased 4.5 million shares this year, with 12 million more to go, aligning with their strategy of benefiting from a lower stock price.
